Inivata, a global clinical cancer genomics company, employs the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare. Inivata’s world leading expertise, cutting-edge technology, and advanced bioinformatics analysis can detect and characterize cancer-related mutations and enable non-invasive testing at multiple points along the cancer care cycle. Using a simple blood test, Inivata’s proprietary technology provides oncologists with clinically actionable information to guide therapy selection, monitor treatment, and detect resistance mutations as they emerge.